Umecrine Ab

Umecrine Cognition Ab

Asarina Pharma Ab

Other

Relmada Therapeutics, Inc.

Umecrine Mood Ab

Torbjörn Bäckström

Ming-De Wang

Gianna Ragagnin

Per Lundgren

Magnus Doverskog

Anders Carlsson

Hanns Möhler

Inga-Maj Johansson

Vicente Felipo

Maja Johansson

Markus Jerling

Pontus Wasling

It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25&#xb0; C. and 0% at 37&#xb0; C. In addition it is provided a method for preparing the pharmaceutical composition.

Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties

The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of Tourette's syndrome, obsessive compulsive disorder and/or gambling disorder, as well as methods for treating said disorders and pharmaceutical compositions for use in treatment of said disorders.

3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment

The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of essential tremor, as well as methods for treating essential tremor and pharmaceutical compositions for use in treatment of essential tremor.

3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor

The invention relates to 3&#x3b1;-ethynyl, 3&#x3b2;-hydroxy, 5&#x3b1;-pregnan-20-oxime, represented by the following structural formula: or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-aminobutyric acid receptor-chloride ionophore (GABA-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.

3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders

The present invention provides the steroidal compound 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.

Steroid compound for use in the treatment of hepatic encephalopathy

There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3&#x3b1;-ethynyl-3&#x3b2;-hydroxy-5&#x3b1;-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

Methods for treating hypersomnolence

The present invention provides the steroidal compound 3&#x25a1;-ethynyl-3&#x25a1;-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.

Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.

Steroids having increased water solubility and resistance against metabolism and methods for their production

Steroids having increased water solubility and resistance against metabolism, and methods for their production

Compounds exhibiting 3alpha-hydroxy-5alpha/beta-steroid blocking action with no or only low antagonism against the gamma-aminobutyric acid (A) receptor (GABA-A), and compounds exhibiting partial antagonism against said receptor are presented. Methods for the prevention, treatment and/or alleviation of various CNS-disorders are suggested, as well as pharmaceutical compositions for such use.

GABA-steroid antagonists and their use for the treatment of CNS disorders

Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.

Pregnane steroids and their use in the treatment of CNS disorders

Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.

Growing community of inventors

Umeå, Sweden

Torbjörn Bäckström